Teva Sues FDA Over Delisted Risperdal Patent

Law360, New York (March 5, 2008, 12:00 AM EST) -- Generic-drug maker Teva Pharmaceuticals USA Inc. has filed suit against the U.S. Food and Drug Administration and two government officials seeking an injunction that would force the regulator to relist a patent for the antipsychotic drug Risperdal.

In a complaint filed Tuesday in the U.S. District Court for the District of Columbia, Teva claims that the FDA delisted the patent after the drug company submitted the first abbreviated new drug application for a generic version of Risperdal, effectively denying Teva an 180-day exclusivity period to market...
To view the full article, register now.